CASI Pharmaceuticals Analyst Ratings
CASI Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2022 | 426.32% | BTIG | $21 → $10 | Maintains | Buy |
| 11/15/2022 | 426.32% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 08/15/2022 | 531.58% | HC Wainwright & Co. | $3 → $12 | Maintains | Buy |
| 06/03/2022 | 1005.26% | BTIG | $4 → $21 | Maintains | Buy |
| 05/16/2022 | 57.89% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 05/18/2021 | 110.53% | BTIG | → $4 | Initiates Coverage On | → Buy |
| 05/14/2021 | 110.53% | HC Wainwright & Co. | $3.5 → $4 | Maintains | Buy |
| 04/26/2021 | 100% | Mizuho | → $3.8 | Initiates Coverage On | → Buy |
| 10/23/2020 | 163.16% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 03/24/2020 | 84.21% | HC Wainwright & Co. | $7 → $3.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/16/2022 | 426.32% | BTIG | $21 → $10 | 維護 | 買 |
| 11/15/2022 | 426.32% | HC Wainwright公司 | $12 → $10 | 維護 | 買 |
| 08/15/2022 | 531.58% | HC Wainwright公司 | $3 → $12 | 維護 | 買 |
| 06/03/2022 | 1005.26% | BTIG | $4 → $21 | 維護 | 買 |
| 05/16/2022 | 57.89% | HC Wainwright公司 | $4 → $3 | 維護 | 買 |
| 05/18/2021 | 110.53% | BTIG | → $4 | 開始承保 | →購買 |
| 05/14/2021 | 110.53% | HC Wainwright公司 | $3.5 → $4 | 維護 | 買 |
| 04/26/2021 | 100% | 瑞穗 | → $3.8 | 開始承保 | →購買 |
| 10/23/2020 | 163.16% | 奧本海默 | → $5 | 開始承保 | →跑贏大盤 |
| 03/24/2020 | 84.21% | HC Wainwright公司 | $7 → $3.5 | 維護 | 買 |
What is the target price for CASI Pharmaceuticals (CASI)?
CASI製藥(CASI)的目標價是多少？
The latest price target for CASI Pharmaceuticals (NASDAQ: CASI) was reported by BTIG on November 16, 2022. The analyst firm set a price target for $10.00 expecting CASI to rise to within 12 months (a possible 426.32% upside). 5 analyst firms have reported ratings in the last year.
卡塔爾國際集團於2022年11月16日報告了CASI製藥公司(納斯達克代碼：CASI)的最新目標價。這家分析公司將目標價定為10美元，預計CASI將在12個月內上漲(可能上漲426.32)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for CASI Pharmaceuticals (CASI)?
CASI製藥(CASI)的最新分析師評級是多少？
The latest analyst rating for CASI Pharmaceuticals (NASDAQ: CASI) was provided by BTIG, and CASI Pharmaceuticals maintained their buy rating.
納斯達克(股票代碼：CASI)的最新分析師評級由貝萊德提供，CASI製藥維持買入評級。
When is the next analyst rating going to be posted or updated for CASI Pharmaceuticals (CASI)?
CASI製藥(CASI)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與CASI製藥的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。CASI製藥的上一次評級是在2022年11月16日提交的，所以你應該預計下一次評級將在2023年11月16日左右的某個時候公佈。
Is the Analyst Rating CASI Pharmaceuticals (CASI) correct?
分析師對CASI製藥(CASI)的評級正確嗎？
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $21.00 to $10.00. The current price CASI Pharmaceuticals (CASI) is trading at is $1.90, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的CASI製藥(CASI)評級維持不變，目標價在21.00美元至10.00美元之間。CASI製藥(CASI)目前的交易價格為1.9美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。